WASHINGTON DC - December 3, 2013 - The American Antitrust Institute (AAI) held its first annual Antitrust Enforcement Awards tonight, honoring litigation achievements in economics and private law practice.
Law360 reports on Hilliard & Shadowen's victory over defendants'
statute of limitations motion for summary judgment in Nexium case:
A Massachusetts federal judge on Wednesday rejected AstraZeneca PLC and Ranbaxy Inc.'s bid to dismiss as time-barred certain claims in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca’s heartburn drug Nexium. U.S. District Judge William G. Young denied AstraZeneca and generics manufacturer Ranbaxy's motion for partial summary judgment on claims relating to Ranbaxy's alleged exclusion from the market because of a settlement agreement between the two companies, saying the plaintiffs have presented evidence supporting their position that the statute of limitations on those claims did not start to run when the agreement was executed in April 2008.